Eikon Therapeutics is a clinical-stage biopharmaceutical company developing oncology medicines to address serious unmet medical needs in cancer treatment. The company leverages a proprietary Single Molecule Tracking platform combined with artificial intelligence to accelerate drug discovery by mapping protein interactions and dynamics in living cells, enabling faster advancement of candidates from discovery to clinical testing. Eikon's pipeline includes multiple advanced clinical programs targeting high-burden cancers such as melanoma, non-small cell lung cancer, ovarian cancer, and brain metastases, with revenue generated through upfront payments and milestone payments from licensing agreements with partner companies, supplemented by eventual commercialization of approved medicines.